Investing
587 Articles
(ALTH) Allos Therapeutics trading down 20% after its Phase III study of Efaproxyn failed to meet primary endpoint of improvement…
Some sectors showed mixed results in the short selling, but the Big Pharma and medical instruments and related companies saw…
Our top personal finance-related articles today. Your wallet will thank you later.